Rigel Pharmaceuticals, Inc.
RIGL
$32.13
$2.769.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -15.41% | 0.11% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -15.74% | 0.49% | |||
| Cost of Revenue | -2.15% | 37.45% | |||
| Gross Profit | -19.99% | -7.31% | |||
| SG&A Expenses | 2.20% | 3.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.65% | 13.62% | |||
| Operating Income | -48.71% | -18.47% | |||
| Income Before Tax | -48.68% | -17.76% | |||
| Income Tax Expenses | 101.22% | -87,525.36% | |||
| Earnings from Continuing Operations | -96.77% | 860.81% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -96.77% | 860.81% | |||
| EBIT | -48.71% | -18.47% | |||
| EBITDA | -47.49% | -18.10% | |||
| EPS Basic | -96.81% | 851.86% | |||
| Normalized Basic EPS | -49.25% | -18.53% | |||
| EPS Diluted | -96.75% | 827.79% | |||
| Normalized Diluted EPS | -48.40% | -20.42% | |||
| Average Basic Shares Outstanding | 1.12% | 0.94% | |||
| Average Diluted Shares Outstanding | -0.55% | 3.33% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||